ScholarIQanswers from OpenAlex & ORCID
Oliver Sartor
ResearcherPublications, citations & collaboration network
Oliver Sartor is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Oliver Sartor have?
ScholarIQindexed works
Oliver Sartor has 1,262 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Oliver Sartor have?
ScholarIQcitation count
Oliver Sartor has 45,927 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Oliver Sartor?
ScholarIQh-index
Oliver Sartor has an h-index of 97 in OpenAlex.
What is the i10-index of Oliver Sartor?
ScholarIQi10-index
Oliver Sartor has an i10-index of 428 in OpenAlex.
What is the ORCID of Oliver Sartor?
ScholarIQorcid
The ORCID for Oliver Sartor is on the source record.
What is the OpenAlex record for Oliver Sartor?
ScholarIQopenalex
The OpenAlex for Oliver Sartor is on the source record.
What are the most-cited papers on Oliver Sartor?
ScholarIQmost cited works
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann S. de Bono, Stéphane Oudard, Mustafa Özgüroğlu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocák, Gwénaëlle Gravis, I. Bodrogi, Mary J. MacKenzie, Liji Shen, Martin Roessner, Sunil Gupta, Oliver Sartor
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann S. de Bono, Kim N., Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El‐Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Pérez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, Tomasz M. Beer, Michael A. Carducci, Kim N., Paul G. Corn, Johann S. de Bono, Robert Dreicer, Daniel J. George, Elisabeth I. Heath, Maha Hussain, Wm. Kevin Kelly, Glenn Liu, Christopher J. Logothetis, David M. Nanus, Mark N. Stein, Dana E. Rathkopf, Susan F. Slovin, Charles J. Ryan, Oliver Sartor, Eric J. Small, Matthew Raymond Smith, Cora N. Sternberg, Mary-Ellen Taplin, George Wilding, Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Glenn J. Bubley, Michael A. Carducci, William L. Dahut, Nancy A. Dawson, Danai Daliani, Mario A. Eisenberger, William D. Figg, Boris Freidlin, Susan Halabi, Gary R. Hudes, Maha Hussain, Richard Kaplan, Charles E. Myers, William Oh, Daniel P. Petrylak, Eddie Reed, Bruce J. Roth, Oliver Sartor, Howard I. Scher, Jonathan W. Simons, Vickie Sinibaldi, Eric J. Small, Matthew R. Smith, Donald L. Trump, Robin T. Vollmer, George Wilding